daratumumab sold brand name darzalex anticancer monoclonal antibody medication binds overexpressed multiple myeloma daratumumab originally developed genmab jointly developed genmab along johnson johnson subsidiary janssen biotech acquired worldwide commercialization rights drug daratumumab granted breakthrough therapy drug status multiple myeloma granted orphan drug status multiple myeloma diffuse large b cell lymphoma follicular lymphoma mantle cell may us food drug administration fda approved daratumumab use combination bortezomib melphalan prednisone include treatment people newly diagnosed multiple myeloma ineligible autologous stem cell european union indicated monotherapy treatment adults relapsed refractory multiple whose prior therapy included proteasome inhibitor immunomodulatory agent demonstrated disease progression last treatment multiple myeloma daratumumab potentially increases patients susceptibility bacterial viral infections due killing natural killer cells main innate immune system defense daratumumab frequently causes human cytomegalovirus cmv reactivation unknown injection related reactions inflammationlike also daratumumab also bind present red blood cells interfere routine testing clinically significant antibodies people show panreactive antibody panel including positive autocontrol tends mask presence clinically significant antibodies treatment antibody panel cells dithiothreitol dtt repeating testing effectively negate binding daratumumab red blood cell surface however dtt also inactivatesdestroys many antigens red blood cell surface disrupting disulfide bonds antigen system affected associated common clinically significant antibodies kell making crossmatch testing knegative rbcs reasonable alternative urgent transfusion therefore advisable baseline antibody screen rh kell phenotyping type screen starting therapy antibody screen negative proceed phenotype matched transfusions therapy antibody screen positive give specific antigen negative blood incompatibility may persist months stopping medicine furthermore blood transfusion centers routinely notified sending sample daratumumab also interfere flow cytometric evaluation multiple myeloma causing apparent lack plasma daratumumab monoclonal antibody directed overexpressed multiple myeloma cells daratumumab binds different epitope aminoacid sequence monoclonal antibody daratumumab binds causing cells apoptose via antibodydependent cellular cytotoxicity complementdependent cytotoxicity inhibition mitochondrial transfer antibodydependent cellular effects dependent upon fragment crystallizable region immune effector antibodydependent cellular cytotoxicity means natural killer unlike isatuximab causes apoptosis directly daratumumab induces apoptosis multiple myeloma cells higher levels show greater daratumumabmediated cell lysis cells low enzyme results formation immunosuppressive substance adenosine eliminating cells increases ability immune system eliminate encouraging preliminary results reported june phase iii clinical trial relapsed multiple myeloma updated trial results presented december indicate daratumumab continuing show promising singleagent antimyeloma study compared monotherapy mgkg monthly weekly daratumumab given priority review status us food drug administration fda multiple myeloma combination therapy second daratumumab phase iii trials multiple myeloma show great promise combination therapy lenalidomide well bortezomib update november us food drug administration fda approved daratumumab treatment multiple myeloma people received least three prior may daratumumab also conditionally approved european medicines agency treatment multiple november fda approved daratumumab combination lenalidomide bortezomib dexamethasone treatment people multiple myeloma received least one prior european commission granted marketing authorisation may httpsenwikipediaorgwikidaratumumab